Ocular Hypertension Clinical Trial
Official title:
The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma.
The purpose of this study is to determine whether a commonly prescribed orally inhaled corticosteroid treatment will induce a clinically meaningful elevation in intraocular pressure, when administered to patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). Based on the response to high-dose corticosteroids, this patient group is more likely than the normal population to demonstrate this adverse effect.
Systemic and topical ophthalmic steroids have long been associated with ocular effects, such
as glaucoma or cataracts.[Alfano JE; Bernstein HN et al. 1962; Bernstein HN et al. 1963;
Becker B and Mills DW in Arch Ophthalm 1963; Becker B and Mills DW in JAMA 1963; Armaly MF
1963 (1); Armaly MF 1963 (2); and Buckley RJ] Periocular steroid injections [Herschler J;
Kalina RE] and steroids applied to periocular skin [Aggarwal RK et al.] have also been
reported to increase intraocular pressure (IOP) and raised IOP is the major risk factor for
glaucoma.
Ocular hypertension (OHT) is defined as an IOP above 21mmHg in one or both eyes without
detectable glaucomatous damage. Primary open-angle glaucoma (POAG) is a chronic and
progressive optic neuropathy of unknown etiology characterized by disc cupping, and often
associated with visual field defects and elevated IOP. This disease is one of the leading
causes of blindness worldwide.[Kwon YH et al.] Approximately 18% to 36% of the general
population are corticosteroid responders. This response is increased to 46% to 92% in
patients with POAG.[Tripathi RC et al.] Asthma is the most common chronic respiratory illness
in Canada, affecting approximately 10% of the population. For the majority of these patients,
long-term inhaled corticosteroids (ICS) are standard of care to prevent acute asthma
exacerbations.[Kim H and Mazza J] Although the systemic absorption of inhaled and nasal
steroids has been established, the clinically relevant ocular side effects are poorly
defined. [Cave A et al.; Allen DB et al.] A large prospective study in 1995 by Samiy et al
reported no statistically significant increase of IOP in 187 patients without glaucoma taking
inhaled steroids for various pulmonary conditions.[Samiy N et al.] However, six cases of
increased IOP associated with combined nasal and inhaled steroid use in non-glaucomatous
patients have been reported. [Dreyer EB; Desnoeck M et al.; Opatowsky I et al.] A large
case-control study in 1997 suggested that current users of high doses of ICS prescribed
regularly for 3 or more months were at increased risk of OHT or OAG (OR 1.44; 95% CI
1.01-2.06).[Garbe E et al.] In contrast, Gozalez et al. conducted a nested case-control study
in 2010 with Quebec data which showed current and continuous use of ICS did not result in
increased risk of glaucoma or raised IOP requiring treatment.[Gonzalez AV et al.] Similarly,
Duh et al. reported no association between inhaled budesonide daily therapy and increased IOP
in 1255 asthmatic patients.[Duh MS et al.] Further, a prospective population-based cohort
study published in 2012 suggested no association between the development of OAG and ICS in
the elderly.[Marcus MW et al.] In 2013, our group published a randomized double-masked
controlled trial that showed no evidence of IOP elevation after 6 weeks use of beclomethasone
nasal spray in 19 patients with OHT and POAG.[Yuen D et al.] The purpose of the current study
protocol would be to extend the study to investigate ICS in the same patient population.
To date, the effect of inhaled corticosteroids in those with pre-existing OHT or POAG remains
uncertain. Considering the large number of patients on inhaled steroids, investigating the
use of inhaled steroid in glaucoma patients could have significant clinical impact. This
study was designed to evaluate the effect of inhaled fluticasone propionate on intraocular
pressure (IOP) in patients with OHT or controlled open-angle glaucoma (OAG).
Patient randomization was performed by an independent Research Coordinator in a separate
physical space and kept sealed from the principal study investigators, who assessed and
recorded outcome measures, until the completion of study data collection. IOP was measured in
a masked fashion, using a second observer to record values. Two measurements within 1 mmHg
were averaged for each data point. With a sample size of 8 patients per interventional arm,
the study is powered at 0.80 to detect an elevation of 3.2 mmHg (≥20%) from mean, assuming a
standard deviation of 2.5 mmHg. Baseline data will be compared between groups using the
student's t test and Fisher exact test. A 2-sided p value of <0.05 will be considered
statistically significant. The primary outcome measure (mean IOP) will be assessed using a
1-sided Student t test.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03284853 -
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT01157364 -
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06441643 -
Next Generation Rocklatan
|
Phase 2 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02792803 -
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
|
Phase 4 | |
Terminated |
NCT02801617 -
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02558374 -
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02993445 -
Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02003547 -
A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01995136 -
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Completed |
NCT01936389 -
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
|
Phase 2 | |
Completed |
NCT01664039 -
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
|
Phase 4 | |
Completed |
NCT01693315 -
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
|
Phase 2 | |
Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
Completed |
NCT01426867 -
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
|
Phase 2 | |
Completed |
NCT01410188 -
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
|
Phase 1/Phase 2 | |
Completed |
NCT01489670 -
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
|
N/A |